Ernexa Therapeutics Inc. (ERNA)
 NASDAQ: ERNA · Real-Time Price · USD
 1.780
 +0.020 (1.14%)
  At close: Oct 30, 2025, 4:00 PM EDT
1.700
 -0.080 (-4.49%)
  Pre-market: Oct 31, 2025, 4:56 AM EDT
Ernexa Therapeutics Revenue
Ernexa Therapeutics had revenue of $488.00K in the twelve months ending June 30, 2025, up 201.23% year-over-year. In the year 2024, Ernexa Therapeutics had annual revenue of $582.00K with 755.88% growth.
Revenue (ttm) 
 $488.00K
Revenue Growth 
 +201.23%
P/S Ratio 
 10.59
Revenue / Employee 
 $81,333
Employees 
 6
Market Cap 
13.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 582.00K | 514.00K | 755.88% | 
| Dec 31, 2023 | 68.00K | - | - | 
| Dec 31, 2022 | - | - | - | 
| Dec 31, 2021 | - | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
ERNA News
- 1 day ago - Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer - PRNewsWire
- 4 weeks ago - Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa - GlobeNewsWire
- 4 weeks ago - Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit - GlobeNewsWire
- 6 weeks ago - Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research - GlobeNewsWire
- 7 weeks ago - Ernexa Therapeutics Provides Update on Operational Excellence and Performance - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 4 months ago - Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development - GlobeNewsWire